FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4225533698> ?p ?o ?g. }

• W4225533698 abstract "You have accessJournal of UrologyCME1 May 2022PD41-09 MOVING BEYOND PSA: IDENTIFYING THE OPTIMAL DIAGNOSTIC STRATEGY TO ASSESS PROSTATE CANCER RISK Douglas Cheung, Diana Magee, Thomas Stonier, Andrew Briggs, Bart Ferket, Antonio Finelli, Girish Kulkarni, Andrew Vickers, Sigrid Carlsson, and James Eastham Douglas CheungDouglas Cheung More articles by this author , Diana MageeDiana Magee More articles by this author , Thomas StonierThomas Stonier More articles by this author , Andrew BriggsAndrew Briggs More articles by this author , Bart FerketBart Ferket More articles by this author , Antonio FinelliAntonio Finelli More articles by this author , Girish KulkarniGirish Kulkarni More articles by this author , Andrew VickersAndrew Vickers More articles by this author , Sigrid CarlssonSigrid Carlsson More articles by this author , and James EasthamJames Eastham More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002602.09AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Diagnostic strategies based on biomarkers and/or magnetic resonance imaging (MRI) may better select men whose PSA test is unlikely to be clinically significant prostate cancer (PCa) from men who may harbor life threatening disease. However, there is limited evidence regarding the combined use of biomarkers with MRI, and which sequence is most efficient. We compared the clinical- and cost-effectiveness of multiple strategies for the diagnosis of PCa. METHODS: A clinical decision tree was constructed (TreeAgePro 2021) to evaluate biomarker and MRI strategies versus systematic biopsy. In addition to solo testing, combination pathways of biomarkers and MRI with sequential testing in positive-reflexive (e.g. to locate the lesion) and negative-reflexive (e.g. to confirm the negative) manners were evaluated. Patients with a positive MRI and/or biomarker were biopsied. The base case was a biopsy-naïve man with a worrisome PSA for initial diagnosis. Our co-primary outcomes were: I) clinically significant (Gleason 3+4 or higher) and II) non-clinically significant PCa, III) biopsies avoided, and IV) mean cost (U.S. [$] and U.K. [£]) per patient. Model parameters were populated from a literature search of electronic databases (i.e. MEDLINE, PubMed). Inputs for diagnostic performance were preferentially identified using template biopsy reference standards. Cost data were selected from primary sources (e.g. governmental agencies) where available. RESULTS: Most combination strategies and MRI-alone were superior to a recommendation that all men with a worrisome PSA test undergo systematic biopsy (Table 1). Additional testing increased detection of clinically significant PCa (1%-19%), reduced overdiagnosing non-clinically significant PCa (2%-18%), while sparing many men from biopsy (5%-26%). There was a modest additional cost from $96-$933/£214-£1,161. Approaches that optimized clinical consequences and cost were biomarker with positive reflexive MRI or MRI followed by negative reflex biomarker. Our results were robust to sensitivity analyses exploring PCa prevalence and target-only biopsy. CONCLUSIONS: Cost-effective pre-biopsy strategies including a combination of MRI and biomarker better identify men at higher risk for clinically significant PCa while avoiding biopsy in lower risk individuals. Source of Funding: D.C.C.'s work was supported in part by the Canadian Institutes of Health Research Canada Graduate Doctoral Scholarship, Hold'em for Life Oncology Clinician Scientist/Fellowship, Canadian Association for Healthcare Reimbursement Research Scholarship, and Clinician Investigator Program-Ministry of Health Scholarship funding. A.B.’s, A.V.’s, S.V.C.’s and J.A.E.’s work was supported in part by funding from National Institutes of Health/National Cancer Institute (P30-CA008748) and Sidney Kimmel Center for Prostate and Urologic Cancers. S.V.C. was further supported by the National Institutes of Health/National Cancer Institute (K22-CA234400 and U01-CA199338-02) and the Prevent Cancer Foundation © 2022 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 207Issue Supplement 5May 2022Page: e692 Advertisement Copyright & Permissions© 2022 by American Urological Association Education and Research, Inc.MetricsAuthor Information Douglas Cheung More articles by this author Diana Magee More articles by this author Thomas Stonier More articles by this author Andrew Briggs More articles by this author Bart Ferket More articles by this author Antonio Finelli More articles by this author Girish Kulkarni More articles by this author Andrew Vickers More articles by this author Sigrid Carlsson More articles by this author James Eastham More articles by this author Expand All Advertisement PDF DownloadLoading ..." @default.
• W4225533698 created "2022-05-05" @default.
• W4225533698 creator A5006239777 @default.
• W4225533698 creator A5007783258 @default.
• W4225533698 creator A5018908850 @default.
• W4225533698 creator A5019479654 @default.
• W4225533698 creator A5025886998 @default.
• W4225533698 creator A5030594142 @default.
• W4225533698 creator A5045696014 @default.
• W4225533698 creator A5060829314 @default.
• W4225533698 creator A5087481089 @default.
• W4225533698 creator A5088388062 @default.
• W4225533698 date "2022-05-01" @default.
• W4225533698 modified "2023-09-23" @default.
• W4225533698 title "PD41-09 MOVING BEYOND PSA: IDENTIFYING THE OPTIMAL DIAGNOSTIC STRATEGY TO ASSESS PROSTATE CANCER RISK" @default.
• W4225533698 doi "https://doi.org/10.1097/ju.0000000000002602.09" @default.
• W4225533698 hasPublicationYear "2022" @default.
• W4225533698 type Work @default.
• W4225533698 citedByCount "0" @default.
• W4225533698 crossrefType "journal-article" @default.
• W4225533698 hasAuthorship W4225533698A5006239777 @default.
• W4225533698 hasAuthorship W4225533698A5007783258 @default.
• W4225533698 hasAuthorship W4225533698A5018908850 @default.
• W4225533698 hasAuthorship W4225533698A5019479654 @default.
• W4225533698 hasAuthorship W4225533698A5025886998 @default.
• W4225533698 hasAuthorship W4225533698A5030594142 @default.
• W4225533698 hasAuthorship W4225533698A5045696014 @default.
• W4225533698 hasAuthorship W4225533698A5060829314 @default.
• W4225533698 hasAuthorship W4225533698A5087481089 @default.
• W4225533698 hasAuthorship W4225533698A5088388062 @default.
• W4225533698 hasConcept C121608353 @default.
• W4225533698 hasConcept C126322002 @default.
• W4225533698 hasConcept C126838900 @default.
• W4225533698 hasConcept C143409427 @default.
• W4225533698 hasConcept C185592680 @default.
• W4225533698 hasConcept C19527891 @default.
• W4225533698 hasConcept C2780192828 @default.
• W4225533698 hasConcept C2781197716 @default.
• W4225533698 hasConcept C29456083 @default.
• W4225533698 hasConcept C55493867 @default.
• W4225533698 hasConcept C71924100 @default.
• W4225533698 hasConceptScore W4225533698C121608353 @default.
• W4225533698 hasConceptScore W4225533698C126322002 @default.
• W4225533698 hasConceptScore W4225533698C126838900 @default.
• W4225533698 hasConceptScore W4225533698C143409427 @default.
• W4225533698 hasConceptScore W4225533698C185592680 @default.
• W4225533698 hasConceptScore W4225533698C19527891 @default.
• W4225533698 hasConceptScore W4225533698C2780192828 @default.
• W4225533698 hasConceptScore W4225533698C2781197716 @default.
• W4225533698 hasConceptScore W4225533698C29456083 @default.
• W4225533698 hasConceptScore W4225533698C55493867 @default.
• W4225533698 hasConceptScore W4225533698C71924100 @default.
• W4225533698 hasIssue "Supplement 5" @default.
• W4225533698 hasLocation W42255336981 @default.
• W4225533698 hasOpenAccess W4225533698 @default.
• W4225533698 hasPrimaryLocation W42255336981 @default.
• W4225533698 hasRelatedWork W1729980350 @default.
• W4225533698 hasRelatedWork W1999344589 @default.
• W4225533698 hasRelatedWork W2143612480 @default.
• W4225533698 hasRelatedWork W2161899978 @default.
• W4225533698 hasRelatedWork W2273540743 @default.
• W4225533698 hasRelatedWork W2340892070 @default.
• W4225533698 hasRelatedWork W2410191098 @default.
• W4225533698 hasRelatedWork W2789448498 @default.
• W4225533698 hasRelatedWork W4243514755 @default.
• W4225533698 hasRelatedWork W4244477365 @default.
• W4225533698 hasVolume "207" @default.
• W4225533698 isParatext "false" @default.
• W4225533698 isRetracted "false" @default.
• W4225533698 workType "article" @default.